Astrana Health (ASTH) Expected to Announce Earnings on Monday

Astrana Health (NASDAQ:ASTH) will likely be announcing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.15 per share and revenue of $930.4570 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Astrana Health Price Performance

ASTH stock opened at $20.33 on Friday. The company’s 50-day moving average price is $23.51 and its two-hundred day moving average price is $26.34. The firm has a market cap of $1.14 billion, a P/E ratio of 107.01, a P/E/G ratio of 0.62 and a beta of 0.90. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.27. Astrana Health has a 12 month low of $18.08 and a 12 month high of $34.80.

Analyst Ratings Changes

A number of research analysts recently issued reports on ASTH shares. Zacks Research cut shares of Astrana Health from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 10th. Needham & Company LLC began coverage on Astrana Health in a report on Friday, December 12th. They issued a “buy” rating and a $28.00 target price on the stock. TD Cowen lowered their price target on Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 10th. Weiss Ratings restated a “sell (d+)” rating on shares of Astrana Health in a research report on Monday, December 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrana Health in a research note on Tuesday, November 25th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.88.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently bought and sold shares of ASTH. Tower Research Capital LLC TRC boosted its stake in shares of Astrana Health by 323.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after purchasing an additional 3,517 shares in the last quarter. State of Wyoming acquired a new position in shares of Astrana Health in the second quarter valued at approximately $132,000. Los Angeles Capital Management LLC bought a new position in Astrana Health in the 4th quarter valued at approximately $228,000. WINTON GROUP Ltd acquired a new stake in Astrana Health during the 2nd quarter worth approximately $233,000. Finally, Brevan Howard Capital Management LP bought a new stake in Astrana Health during the 2nd quarter worth approximately $277,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.